Term
|
Definition
|
|
Term
|
Definition
| competitive alpha antagonist |
|
|
Term
|
Definition
| non-selective alpha antagonist |
|
|
Term
|
Definition
|
|
Term
|
Definition
|
|
Term
|
Definition
|
|
Term
| are antagonists more effective against exogenous or endogenous agonists? |
|
Definition
|
|
Term
|
Definition
| alpha antagonism to reduce release of epinephrine |
|
|
Term
|
Definition
| alpha antagonist to treat |
|
|
Term
| dually innervated part of eye and its control |
|
Definition
| spincter muscle (PS) and radial muscle (A-1) control dilation. Muscarinic tone tries to close aperture (nearsightedness) |
|
|
Term
| singly innervated portion of eye |
|
Definition
| ciliary muscle (PS) increase agonism for nearsightedness, decrease agonism for farsightedness |
|
|
Term
| paralysis of accomodation cause |
|
Definition
| muscarinic antagonism (only) |
|
|
Term
|
Definition
|
|
Term
| kidney receptors and response |
|
Definition
| B-1 JGA leads to renin release and hypertension |
|
|
Term
| uterine sympathetic receptors |
|
Definition
| B-2, prevents contraction |
|
|
Term
| liver sympathetic receptors, response |
|
Definition
| B-2, glyconeogenesis, glycolysis |
|
|
Term
| catecholamine synthetic pathway |
|
Definition
| phenylalanine, tyrosine, dihydroxyphenylalanine (DOPA), dopamine, norepinephrine, epinephrine |
|
|
Term
| function of tyrosine hydroxylase |
|
Definition
|
|
Term
| aromatic amino acid decarboxylase function |
|
Definition
|
|
Term
| dopamine B-hydroxylase function |
|
Definition
| oxidize dopamine to norepinephrine |
|
|
Term
| non adrenergics that prevent aqueous humor formation |
|
Definition
| prostaglandins and carbonic anhydrase inhibitors |
|
|
Term
| tertiary amine muscarinic antagonists |
|
Definition
| trihexyphenidyl; tropicamide; benztropine |
|
|
Term
|
Definition
| tertiary amine anticholinergic |
|
|
Term
|
Definition
| tertiary amine anticholinergic |
|
|
Term
|
Definition
| tertiary amine anticholinergic |
|
|
Term
|
Definition
| nicotine, trimethaphan, hexamethonium, mecamylamine |
|
|
Term
|
Definition
| emergency BP lowering; dissecting aortic aneurism |
|
|
Term
|
Definition
| neostigme, pyridostigme, adrephonium, ambenomium, demecarium |
|
|
Term
|
Definition
| physostigme, rivastigme, tacrin, donepezil, edrophonium |
|
|
Term
|
Definition
| MG, paralytic ileum, alzheimers (rivastigme), urinary |
|
|
Term
|
Definition
| antidote non-depolarizing NM blockers, terminate paroxysmal superventricular tachycardia, antidote atropine intoxication (physostigmine) |
|
|
Term
|
Definition
| reactivators of AChE; not effective against carbamylated molecules |
|
|
Term
|
Definition
| aminosteroid nondepolarizing neuromuscular blocker |
|
|
Term
|
Definition
| aminosteroid nondepolarizing nueromuscular blocker |
|
|
Term
|
Definition
| aminosteroid nondepolarizing neuromuscular blocker |
|
|
Term
|
Definition
| benzo nondepolarizing neuromuscular blocker |
|
|
Term
|
Definition
| benzo nondepolarizing neuromuscular blocker |
|
|
Term
|
Definition
| benzo nondepolarizing neuromuscular blocker |
|
|
Term
|
Definition
| benzo nondepolarizing neuromuscular blocker |
|
|
Term
| nondepolarizing benzylosiquinolinium neuromuscular blockers |
|
Definition
| d-tuburcurarine, mivacurium, metocurine, atracurium, alcuronium |
|
|
Term
| aminosteroid nondepolarizing neuromuscular blockers |
|
Definition
| vecuronium, pancuronium, rocuronium |
|
|
Term
| succinyl choline ganglionic blockade? |
|
Definition
| no, but histamine release yes |
|
|
Term
| pancuronium and succinylcholine ANS effects |
|
Definition
| pancuronium sympathetic stimulation, succinylcholine vagal stimulation |
|
|
Term
|
Definition
| plasma esterase plus spontaneous degredation |
|
|
Term
|
Definition
| direct neuromuscular blocker; locks up calcium and prevents neurotransmitter release; interferes with phasic contractions (spasms) only. no effect on tettanic contractions |
|
|
Term
| sympathetic endocrine effects |
|
Definition
| modulation of renin secretion, modulation of pancreatic secretions, secretion of anterior pituitary (dopamine) |
|
|
Term
| alpha methyl norepinephrine |
|
Definition
|
|
Term
|
Definition
alpha 2 agonist
creates dry mouth as type "b" effect |
|
|
Term
| clonidine-specific therapeutic use |
|
Definition
| reduces withdrawal symptoms without opiate effects |
|
|
Term
| sympathomimetic CNS effects |
|
Definition
| decreased appetite, increased wakefulness |
|
|
Term
|
Definition
| none, it has an isomer that agonizes beta-2 and alpha-1 |
|
|
Term
|
Definition
| DOPAMINE, alpha-1, beta-1 |
|
|
Term
|
Definition
| beta 1 and beta 2 agonism |
|
|
Term
|
Definition
| increased PR, +inotrop, +chronotrope |
|
|
Term
|
Definition
|
|
Term
|
Definition
| alpha-2 agonist for glaucoma |
|
|
Term
|
Definition
| shock by continuous infusion, increase JGD filtration |
|
|
Term
|
Definition
|
|
Term
|
Definition
some types of shock w/oliguria
adverse: 10% tachycardia |
|
|
Term
|
Definition
|
|
Term
| reuptake inhibition and indirect sympathomimetic activity |
|
Definition
| no agonistic activity; indirect sympathomimetic must get into the nerve to have an effect |
|
|
Term
| histamine and vagal nerve |
|
Definition
| decreases firing/increases heartrate |
|
|
Term
|
Definition
|
|
Term
| epinephrine's metabolic effects |
|
Definition
| increases lactate in muscle; inhibits insulin release (A-2); promotes glucagon release (B-2); increase cAMP; increase phosphorylase in liver; glycolysis; G-1-P; G-6-P; increase adipose lipase; |
|
|
Term
| noncetecholamine alpha agonists (4) |
|
Definition
| phenylephrine, menoxamine, metaraminol, mephentermine |
|
|
Term
|
Definition
| IAS is its major classification but it has mixed properties as well as CNS effects |
|
|
Term
|
Definition
| more CNS acting than amphetamine |
|
|
Term
|
Definition
| false transmitter, full agonist on A-2, affinity but no other activity on other receptors |
|
|
Term
| more potent methylated carbon on choline esters |
|
Definition
| beta. the carbamate ester of beta methyl choline is bethanacol |
|
|
Term
|
Definition
| BPH, pheochromocytoma, autonomic hyperreflexia in spinal cord transection |
|
|
Term
|
Definition
ergonavine, ergotamine, ergotoxine;
partial agonists |
|
|
Term
|
Definition
| powerful oxytocic; used to treat Prinzmetal's Angina |
|
|
Term
| ergonavine adverse events |
|
Definition
| gangarene, ergotism, can lead to infarct due to vasoconstriction, |
|
|
Term
|
Definition
| more antagonistic properties: dihidroergotamine; dihidroergotoxin |
|
|
Term
| nonselective beta antagonists (4) |
|
Definition
| propranolol, timolol, nadolol, pindolol |
|
|
Term
| selective beta-1 antagonists |
|
Definition
| metoproplol, atenolol, acebutolol, esmolol |
|
|
Term
|
Definition
| non selective beta 2 antagonist, not metabolized in vivo; mostly PNS, particularly compared to propranolol; used for heart disease and angina |
|
|
Term
|
Definition
| can mask hypoglycemia; non-specific beta antagonist |
|
|
Term
|
Definition
| beta-1 selective antagonist; can mask tachycardia due to hypoglycemia |
|
|
Term
|
Definition
| for exam purposes is nonselective beta antagonist |
|
|
Term
| which beta antagonist has the most intrinsic sympathomimetic activity |
|
Definition
|
|
Term
| which beta antagonist has the greatest lipid solubility |
|
Definition
|
|
Term
| which beta antagonist has the greatest membrane stabilizing capacity |
|
Definition
|
|
Term
| which beta antagonists have the longest/shortest half lives |
|
Definition
| nadolol 10+ hours; esmolol 0.1 hours |
|
|
Term
| carvedilol specific therapy with cardiac insufficiency |
|
Definition
| has some inverse agonistic properties which lead to reverse inotrope and chronotrope benefits |
|
|
Term
|
Definition
| in tachycardia after cardiac surgery when other beta blockers have worn off; administered by continuous infusion |
|
|
